Zobrazeno 1 - 10
of 14
pro vyhledávání: '"J. Andrew Bristol"'
Autor:
Steven Hubert, John F. Kokai-Kun, Giovanni Widmer, Annie Jones, Todd Parsley, Nur A. Hasan, Sheila Connelly, Perrti Koski, J. Andrew Bristol, Michael Kaleko, Saul Tzipori, Poorani Subramanian, Joseph Sliman
Publikováno v:
Anaerobe. 41:58-67
The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex ecosystem that can be disrupted by antibiotic use. The ensuing dysbiosis is conducive to the emergence of opportunistic pathog
Autor:
J. Andrew Bristol, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Kenneth C. Lasseter, Olivia Coughlin, Tracey Roberts, Steven Hubert, Barbara Valero Lopez, James Longstreth
Publikováno v:
Clinical Drug Investigation. 36:725-734
SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous β-lactam antibiotics like cephalosporins. SYN-004 is intended to degrade residual antibiotics excreted into the intestine as a result o
Publikováno v:
International journal of toxicology. 35(3)
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be administered orally to patients receiving intravenous β-lactam antibiotics including cephalosporins. SYN-004 is intended to degra
Autor:
Hong Ji, David L. Ennist, Mingzhu Zhu, J. Andrew Bristol, Mervat Mina, Suzanne Forry-Schaudies, Yuefeng Xie
Publikováno v:
Journal of Virology. 79:5455-5465
Historically, the adenoviral E3 region was found to be nonessential for viral replication in vitro. In addition, adenoviruses whose genome was more than approximately 105% the size of the native genome were inefficiently packaged. These profound obse
Autor:
Paul L. Hallenbeck, J. Andrew Bristol, Kiran Sakhuja, Dawn B. Kayda, Michael Kaleko, Yvette Hudson, John L. Jakubczak, Sheila Connelly, David L. Ennist, Kevin D. Burroughs
Publikováno v:
Cancer Gene Therapy. 11:92-102
Oncolytic adenoviral vectors selectively replicate in and lyse human tumor cells, providing a promising means for targeted tumor destruction. However, oncolytic vectors have limited capacity for incorporation of additional genetic material that could
Publikováno v:
The Journal of Immunology. 167:4286-4292
In this study, we developed a mouse model of adoptive immunotherapy reflecting immune recognition of syngeneic tumor cells naturally expressing an endogenous rejection Ag. Specifically, in a pulmonary metastases model, we examined the potency and mai
Autor:
Sheila Connelly, Neeraja Idamakanti, Michael Kaleko, J. Andrews, Angela M. Gallo-Penn, J. Andrew Bristol
Publikováno v:
Human Gene Therapy. 12:1651-1661
Hemophilia A patients are typically treated by factor VIII (FVIII) protein replacement, an expensive therapy that induces FVIII-specific inhibitors in approximately 30% of patients with severe hemophilia. FVIII gene therapy has the potential to impro
Publikováno v:
Molecular Therapy. 2:223-232
While much is known about adenovirus biology from its development as a therapeutic gene delivery vehicle, an important question remains regarding the appropriate in vivo vector dose. We describe here an in vivo dose threshold effect with an adenovira
Publikováno v:
The Journal of Immunology. 160:2433-2441
We recently identified a murine mutant Ras p21 CD8+ CTL epitope reflecting residues 4 to 12, containing the mutation of Gly to Val at codon 12, that bound weakly to H-2Kd in vitro and generated a weak primary CTL response in immunized BALB/c mice. He
Autor:
J. Andrew Bristol, Michael Kaleko, Saul Tzipori, Kevin Huynh, Steven Hubert, Giovanni Widmer, Joseph Sliman, Jean Mukherjee, Sheila Connelly
Publikováno v:
Gastroenterology. 148:S-1195